Navigation Links
Cancer breakthrough to prevent heart failure and increase survival rates
Date:2/9/2011

A breakthrough by scientists at Queen's University Belfast could help reduce heart failure in cancer patients around the world, and ultimately increase survival rates.

Scientists at Queen's Centre for Vision and Vascular Science have discovered the role of an enzyme which, when a patient receives chemotherapy, can cause life-threatening damage to the heart. This has, until now, restricted the amount of chemotherapy doses a patient can receive; but while protecting the heart, this dilutes the chemotherapy's effectiveness in destroying cancerous tumours.

By identifying the role of the enzyme - NADPH oxidase - work can now go ahead into making chemotherapy treatments more effective and reduce the toxic effects of cancer treatment on the heart.

Dr David Grieve, jointly leading on the research at Queen's School of Medicine, Dentistry and Biomedical Sciences said: "While chemotherapy drugs are highly effective in treating a wide range of tumours, they can also cause irreversible damage to the heart. This means that doctors are restricted in the doses they can administer to patients. In recent years, scientists have been searching for new drugs to prevent these side-effects.

"Although we have known about the NADPH oxidase enzyme for many years, until now, we were not aware of its crucial role in causing heart damage associated with chemotherapy. Our research findings hold clear potential for the creation of new drugs to block the action of the enzyme, which could significantly reduce heart damage in cancer patients.

"Ultimately, this could allow for the safer use of higher doses of chemotherapy drugs and make the treatment more effective against tumours. Despite improved treatments, cancer is currently responsible for 25 per cent of all mortality in the western world. By reducing the risk of heart failure associated with chemotherapy, patient survival rates could be significantly increased."

Scientists at Queen's are now concentrating their efforts on further studies to define the precise role of NADPH oxidase in the development of heart failure associated with cancer therapies. It is hoped that these may lead to the development of a drug which would have the potential to save lives among cancer patients.


'/>"/>

Contact: Anne-Marie Clarke
anne-marie.clarke@qub.ac.uk
44-028-909-75320
Queen's University Belfast
Source:Eurekalert

Related biology news :

1. Photodynamic therapy against cancer
2. Sweeping view of prostate cancer genome yields deep insights
3. Research team honored for innovative science to advance cancer research
4. Blood-clotting protein linked to cancer and septicemia
5. Discovery may lead to turning back the clock on ovarian cancer
6. Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
7. Early tests find nanoshell therapy effective against brain cancer
8. Scientists synthesize long-sought-after anticancer agent
9. Cornell Dots that light up cancer cells go into clinical trials
10. Antibiotic offers potential for anti-cancer activity
11. Cancer drug aids the regeneration of spinal cord injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: